Assembly Biosciences Inc. (NASDAQ: ASMB)
$15.18
+0.3800 ( +2.57% ) 13.1K
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Market Data
Open
$15.18
Previous close
$14.80
Volume
13.1K
Market cap
$97.53M
Day range
$13.79 - $15.61
52 week range
$7.69 - $20.04
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Mar 15, 2024 |
3 | Insider transactions | 2 | Mar 15, 2024 |
8-k | 8K-related | 14 | Feb 13, 2024 |
8-k | 8K-related | 12 | Feb 02, 2024 |
4 | Insider transactions | 1 | Jan 19, 2024 |
8-k | 8K-related | 10 | Jan 17, 2024 |
def | Proxies and info statements | 6 | Dec 21, 2023 |
pre | Proxies and info statements | 6 | Dec 11, 2023 |
3 | Insider transactions | 2 | Dec 11, 2023 |
8-k | 8K-related | 13 | Dec 07, 2023 |